A Phase I Study to Assess the Safety and Pharmacokinetics of Telaprevir (VX-950) in Subjects With Moderate and Severe Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 14 May 2015
At a glance
- Drugs Telaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen Infectious Diseases BVBA
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2012 Additional locations [Czech Republic, Germany, Poland] identified as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.